Formulations for treating cluster symptoms associated with autism spectrum disorder
The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.
1. A method of reducing agitation in a patient with autism spectrum disorder (ASD), said method comprising administering a pharmaceutical composition to the patient, wherein the pharmaceutical composition comprises:
(a) a Cannabinoid Profile comprising Tetrahydrocannabinol (THC) and Cannabidiol (CBD) at a THC: CBD ratio of 1:1 by weight; and
(b) a Terpene Profile comprising a-Pinene, Valencene, and Eucalyptol.
2. The method of claim 1 , wherein the Terpene Profile comprises 25%-35% α-Pinene by weight, 25%-35% Valencene by weight, and 30%-40% Eucalyptol by weight, wherein the total of % α-Pinene+ % Valencene+ % Eucalyptol=100%.
3. The method of claim 1 , wherein the pharmaceutical composition comprises about 31% α-Pinene by weight, about 31% Valencene by weight, and about 37.5% Eucalyptol by weight.
4. The method of claim 1 , wherein the ratio of the Cannabinoid Profile to Terpene Profile is between 10:1 and 5:1 by weight.
5. The method of claim 1 , wherein the pharmaceutical composition is peppermint flavored.
6. The method of claim 1 , wherein the pharmaceutical composition is vanilla flavored.
7. The method of claim 1 , wherein the pharmaceutical composition is lemon flavored.
8. The method of claim 1 , wherein the pharmaceutical composition is orange flavored.
9. The method of claim 1 , wherein the pharmaceutical composition is ginger flavored.
10. The method of claim 1 , wherein the pharmaceutical composition is passionfruit flavored.
11. The method of claim 1 , wherein the pharmaceutical composition further comprises olive oil.
12. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
13. The method of claim 1 , wherein the pharmaceutical composition is formulated as a liquid dose.
14. The method of claim 13 , wherein the liquid dose is about 2.5 mL.
15. The method of claim 13 , wherein the liquid dose is about 5 mL.
16. The method of claim 1 , wherein the total amount of CBD and THC in the pharmaceutical composition is 300 mg.
17. The method of claim 1 , wherein the pharmaceutical composition comprises from 125 mg to 175 mg of CBD.
18. The method of claim 1 , wherein the pharmaceutical composition comprises from 125 mg to 175 mg of THC.
19. The method of claim 1 , wherein the pharmaceutical composition comprises about 5 mg/mL THC, about 5 mg/mL CBD, about 0.43 mg/mL a-pinene, about 0.43 mg/mL valencene, and about 0.5 mg/mL eucalyptol.